

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Andrew David Morley et al. Art Unit : 1626
Serial No. : 10/542,044 Examiner : Rebecca L. Anderson
Filed : July 13, 2005 Confirmation No.: 8677
Notice of Allowance Date: February 25, 2009
Title : THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2

MAIL STOP ISSUE FEE


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE OF ALLOWANCE

In response to the Notice of Allowance mailed February 25, 2009, enclosed is a completed issue fee transmittal form PTOL 85b. The fees in the amount of \$1,810 for the issue fee (\$1,510) and the publication fee (\$300) are being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account authorization. Please apply all charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-460US1/100928-1P US.

Respectfully submitted,

Date: May 21, 2009


John T. Kendall, Ph.D.
Reg. No. 50,680

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

22191599.doc

CERTIFICATE OF MAILING BY EFS-WEB FILING

I hereby certify that this paper was filed with the Patent and Trademark Office using the EFS-WEB system on this date: May 21, 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Andrew David Morley et al. Art Unit : 1626
Serial No. : 10/542,044 Examiner : Rebecca L. Anderson
Filed : July 13, 2005 Confirmation No.: 8677
Notice of Allowance Date: February 25, 2009
Title : THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2

MAIL STOP ISSUE FEE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMENTS ON EXAMINER'S REASONS FOR ALLOWANCE

Applicants file herewith a Response to Notice of Allowance, completed issue fee transmittal form PTOL-85b, and the required issue fee payment. However, in doing so, Applicants do not agree that there are no other reasons for patentability of the allowed claims (or any other claims for that matter). Nor do Applicants necessarily agree in full with the Reasons and any negative inferences that flow there from.

Please apply any additional charges or credits to our Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-460US1/100928-1P US.

Respectfully submitted,

Date: May 21, 2009


John T. Kendall, Ph.D.
Reg. No. 50,680

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (877) 769-7945

22198841.doc

CERTIFICATE OF MAILING BY EFS-WEB FILING

I hereby certify that this paper was filed with the Patent and Trademark Office using the EFS-WEB system on this date: May 21, 2009

PART B – FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

26164 7590 02/25/2009

FISH & RICHARDSON P.C.
P.O. Box 1022
Minneapolis, MN 55440-1022

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|------------------------------|------------------|
| 10/542,044 | 07/13/2005 | Andrew David Morley | 06275-460US1/100928-1P US | 8677 |

TITLE OF INVENTION: THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2

| APPLN. TYPE | SMALL ENTITY | ISSUE FEE | PUBLICATION FEE | TOTAL FEE(S) DUE | DATE DUE |
|----------------------|--------------|-----------|-----------------|------------------|------------|
| nonprovisional | NO | \$1510 | \$300 | \$1810 | 05/25/2009 |
| EXAMINER | | ART UNIT | CLASS-SUBCLASS | | |
| ANDERSON, REBECCA L. | | 1626 | | | |

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

"Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1. Fish & Richardson P.C.

2. _____

3. _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE (CITY and STATE OR COUNTRY)

AstraZeneca AB

Sweden

Please check the appropriate assignee category or categories (will not be printed on the patent): individual corporation or other private group entity government

4a. The following fee(s) are enclosed:

Issue Fee
 Publication Fee (No small entity discount permitted)
 Advance Order - # of Copies _____

4b. Payment of Fee(s):

A check in the amount of the fee(s) is enclosed.
 Payment by credit card. Form PTO-2038 is attached.
 The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number 06-1050.


5. **Change in Entity Status** (from status indicated above)

a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered agent or; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

(Authorized Signature)



(Date) May 21, 2009

Typed or Printed Name

John T. Kendall, Ph.D.

Registration No. 50,680

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT THIS FORM WITH FEE(S)